Noile-Immune Biotech Inc.
4893.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.77 | 0.38 | -0.20 | -0.15 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -19.13 | 0.00 | -10.48 | -15.22 |
| Quality | ||||
| ROIC | -4.76% | -3.96% | -5.38% | -3.74% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -72.20% | -17.61% | -18.31% | 14.91% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 21.43 | 0.00 | 18.67 | 26.41 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 2,682.13 | 739.67 | 2,407.39 | 2,808.32 |